Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake

Rhea-AI Filing Summary

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 5,963,936 shares of Design Therapeutics, Inc. common stock, including 510,200 shares issuable upon exercise of call options. This represents 9.5% of the common stock, based on 62,456,974 shares outstanding as of April 23, 2026. The shares are held by investment funds managed by Sirenia, with Sirenia and Silverstein sharing voting and dispositive power. SILV Fund, Ltd. has the right to receive dividends or sale proceeds from more than 5% of the outstanding common stock. The reporting persons disclaim admission of beneficial owner status for Section 13 purposes and have entered into a Joint Filing Agreement.

Key Figures

Beneficially owned shares: 5,963,936 shares Ownership percentage: 9.5% Shares outstanding: 62,456,974 shares +2 more

5 metrics

Beneficially owned shares 5,963,936 shares Design Therapeutics common stock reported by Sirenia and Alex Silverstein

Ownership percentage 9.5% Portion of Design Therapeutics common stock class beneficially owned

Shares outstanding 62,456,974 shares Design Therapeutics common stock outstanding as of April 23, 2026

Shares via call options 510,200 shares Common stock issuable upon exercise of call options included in beneficial ownership

CUSIP 25056L103 CUSIP number for Design Therapeutics common stock

Key Terms

beneficial owner, Schedule 13G, shared voting power, shared dispositive power, +1 more

5 terms

beneficial owner regulatory

"the beneficial owner of the securities reported herein"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Schedule 13G regulatory

"have agreed to file this jointly in accordance with the provisions of Rule 13d-1(k)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

shared voting power financial

"Shared Voting Power 5,963,936.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 5,963,936.00"

Joint Filing Agreement regulatory

"have entered into a Joint Filing Agreement, a copy of which is filed"

FAQ

What percentage of Design Therapeutics (DSGN) does Sirenia Capital report owning?

Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 9.5% of Design Therapeutics’ common stock. This is based on 5,963,936 shares compared with 62,456,974 shares outstanding as of April 23, 2026.

How many Design Therapeutics (DSGN) shares does Sirenia Capital beneficially own?

The reporting persons disclose beneficial ownership of 5,963,936 shares of Design Therapeutics common stock. This total includes 510,200 shares issuable upon exercise of call options held by investment funds managed by Sirenia.

What portion of Sirenia’s Design Therapeutics (DSGN) position is via options?

Sirenia’s reported position includes 510,200 shares of Design Therapeutics common stock issuable upon exercise of call options. These option-related shares form part of the total 5,963,936 shares reported as beneficially owned.

Who are the reporting persons in the Design Therapeutics (DSGN) Schedule 13G?

The Schedule 13G is filed by Sirenia Capital Management LP and Alex Silverstein. Silverstein is the managing member of Sirenia’s general partner, and they report on shares held by funds Sirenia manages, subject to a Joint Filing Agreement.

Which entity has rights to more than 5% of Design Therapeutics (DSGN) dividends or sale proceeds?

The filing states that SILV Fund, Ltd. has the right to receive, or direct the receipt of, dividends or proceeds from the sale of more than 5% of Design Therapeutics’ outstanding common stock, linked to the reported holdings.

What share count did Design Therapeutics (DSGN) report outstanding for this Schedule 13G calculation?

The ownership percentage is calculated using 62,456,974 shares of Design Therapeutics common stock outstanding. This figure is taken from the company’s Form 10-Q for the quarter ended March 31, 2026, as of April 23, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 08:33 AM Accepted by SEC EDGAR 08/14/2026 - 08:32 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Design Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

25056L103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 25056L103

1

Names of Reporting Persons

Sirenia Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,963,936.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,963,936.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,963,936.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Includes 510,200 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of call options.

SCHEDULE 13G

CUSIP Number(s): 25056L103

1

Names of Reporting Persons

Alex Silverstein

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,963,936.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,963,936.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,963,936.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 510,200 shares of Common Stock issuable upon exercise of call options.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Design Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Sirenia Capital Management LP ("Sirenia") with respect to the common stock, par value $0.0001 per share ("Common Stock"), of Design Therapeutics, Inc. (the "Issuer") held by (and underlying options held by) investment funds it manages (collectively, the "Sirenia Funds"); and (ii) Alex Silverstein ("Mr. Silverstein"), the managing member of Sirenia Capital Management GP LLC, the general partner of Sirenia, with respect to the Common Stock held by (and underlying options held by) the Sirenia Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934 (the "Act"), the beneficial owner of the securities reported herein. Sirenia and Mr. Silverstein have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of Sirenia and Mr. Silverstein is 1674 Meridian Avenue, Suite 320, Miami Beach, FL 33139.
(c)	Citizenship: Sirenia is a Delaware limited partnership. Mr. Silverstein is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 25056L103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 62,456,974 shares of Common Stock outstanding as of April 23, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on April 28, 2026.
(b)	Percent of class: 9.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). SILV Fund, Ltd. has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Item 2(a) and Item 3.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sirenia Capital Management LP

Signature:	/s/ Kolby Loft
Name/Title:	Kolby Loft, General Counsel & Chief Compliance Officer
Date:	08/14/2026

Alex Silverstein

Signature:	/s/ Alex Silverstein
Name/Title:	Alex Silverstein, individually
Date:	08/14/2026

Exhibit Information

Exhibit 99.1: Joint Filing Agreement